Anzeige
Mehr »
Login
Freitag, 10.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLU4 | ISIN: US14070B3096 | Ticker-Symbol: 4LN2
Frankfurt
10.05.24
15:29 Uhr
4,960 Euro
+0,180
+3,77 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CAPRICOR THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CAPRICOR THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,8205,02022:00
4,8255,03022:00

Aktuelle News zur CAPRICOR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCapricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting1
MiCapricor Therapeutics to Present at Upcoming Scientific and Medical Conferences3
29.04.CAPRICOR THERAPEUTICS, INC. - 8-K, Current Report5
24.04.Capricor Announces Positive Type-B Interaction With FDA For CAP-1002 In Treating DMD1
24.04.Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers8
24.04.Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy126-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and...
► Artikel lesen
22.03.Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers50
21.03.Capricor Therapeutics to Present at Upcoming Investor Conferences5
11.03.CAPRICOR THERAPEUTICS, INC. - 10-K, Annual Report4
06.03.Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference7
02.03.Capricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcript5
01.03.Earnings call: Capricor reports CAP-1002 progress, financials & outlook3
01.03.Capricor Therapeutics Inc reports results for the quarter ended in December - Earnings Summary4
29.02.Capricor Therapeutics GAAP EPS of -$0.02 beats by $0.18, revenue of $12.08M beats by $1.48M4
29.02.CAPRICOR THERAPEUTICS, INC. - 8-K, Current Report2
29.02.Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update277-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4...
► Artikel lesen
28.02.Capricor Therapeutics Q4 2023 Earnings Preview1
28.02.Capricor Therapeutics' Earnings Outlook3
27.02.Capricor Therapeutics Granted Type-B Meeting With FDA For CAP-1002 Muscular Dystrophy Drug, Stock Up2
27.02.Capricor gears up for FDA meeting on drug launch plans4
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1